Xvivo Perfusion Valuation
Is XVIVOS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of XVIVOS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: XVIVOS (SEK448.75) is trading below our estimate of fair value (SEK777.22)
Significantly Below Fair Value: XVIVOS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for XVIVOS?
Other financial metrics that can be useful for relative valuation.
| What is XVIVOS's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 14.19b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 18.3x |
| Enterprise Value/EBITDA | 164.8x |
| PEG Ratio | 5.2x |
Price to Earnings Ratio vs Peers
How does XVIVOS's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 47.3x | ||
AMS Advanced Medical Solutions Group | 44.9x | 23.0% | UK£506.3m |
TSTL Tristel | 30.8x | 17.5% | UK£193.5m |
CTEC ConvaTec Group | 37.2x | 21.0% | UK£4.4b |
CRW Craneware | 76.4x | 24.3% | UK£685.1m |
XVIVOS Xvivo Perfusion | 69.5x | 13.4% | SEK 14.2b |
Price-To-Earnings vs Peers: XVIVOS is expensive based on its Price-To-Earnings Ratio (69.5x) compared to the peer average (47.1x).
Price to Earnings Ratio vs Industry
How does XVIVOS's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: XVIVOS is expensive based on its Price-To-Earnings Ratio (69.5x) compared to the European Medical Equipment industry average (30.5x).
Price to Earnings Ratio vs Fair Ratio
What is XVIVOS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 69.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate XVIVOS's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 448.75 | SEK 547.33 +22.0% | 6.4% | SEK 584.00 | SEK 480.00 | n/a | 6 |
| Oct ’25 | n/a | SEK 549.00 0% | 6.6% | SEK 584.00 | SEK 480.00 | n/a | 6 |
| Sep ’25 | n/a | SEK 549.00 0% | 6.6% | SEK 584.00 | SEK 480.00 | n/a | 6 |
| Aug ’25 | n/a | SEK 549.00 0% | 6.6% | SEK 584.00 | SEK 480.00 | n/a | 6 |
| Jul ’25 | SEK 415.50 | SEK 440.00 +5.9% | 13.9% | SEK 520.00 | SEK 340.00 | n/a | 6 |
| Jun ’25 | SEK 430.00 | SEK 408.00 -5.1% | 12.0% | SEK 468.00 | SEK 340.00 | n/a | 6 |
| May ’25 | SEK 359.00 | SEK 408.00 +13.6% | 12.0% | SEK 468.00 | SEK 340.00 | n/a | 6 |
| Apr ’25 | SEK 273.00 | SEK 382.60 +40.1% | 9.0% | SEK 425.00 | SEK 340.00 | n/a | 5 |
| Mar ’25 | n/a | SEK 382.60 0% | 9.0% | SEK 425.00 | SEK 340.00 | n/a | 5 |
| Feb ’25 | SEK 303.00 | SEK 389.60 +28.6% | 7.8% | SEK 425.00 | SEK 340.00 | n/a | 5 |
| Jan ’25 | SEK 329.25 | SEK 377.00 +14.5% | 16.3% | SEK 450.00 | SEK 280.00 | n/a | 5 |
| Dec ’24 | n/a | SEK 363.75 0% | 17.1% | SEK 450.00 | SEK 280.00 | n/a | 4 |
| Nov ’24 | n/a | SEK 371.67 0% | 18.8% | SEK 450.00 | SEK 280.00 | n/a | 3 |
| Oct ’24 | n/a | SEK 391.67 0% | 11.5% | SEK 450.00 | SEK 340.00 | n/a | 3 |
| Sep ’24 | n/a | SEK 391.67 0% | 11.5% | SEK 450.00 | SEK 340.00 | n/a | 3 |
| Aug ’24 | n/a | SEK 376.67 0% | 7.2% | SEK 405.00 | SEK 340.00 | n/a | 3 |
| Jul ’24 | n/a | SEK 376.67 0% | 7.2% | SEK 405.00 | SEK 340.00 | SEK 415.50 | 3 |
| Jun ’24 | n/a | SEK 376.67 0% | 7.2% | SEK 405.00 | SEK 340.00 | SEK 430.00 | 3 |
| May ’24 | SEK 281.50 | SEK 370.00 +31.4% | 7.2% | SEK 405.00 | SEK 340.00 | SEK 359.00 | 3 |
| Apr ’24 | n/a | SEK 354.00 0% | 8.7% | SEK 385.00 | SEK 312.00 | SEK 273.00 | 3 |
| Mar ’24 | n/a | SEK 365.50 0% | 9.1% | SEK 400.00 | SEK 312.00 | n/a | 4 |
| Feb ’24 | SEK 209.50 | SEK 365.50 +74.5% | 9.1% | SEK 400.00 | SEK 312.00 | SEK 303.00 | 4 |
| Jan ’24 | n/a | SEK 357.50 0% | 11.3% | SEK 400.00 | SEK 291.00 | SEK 329.25 | 4 |
| Dec ’23 | SEK 194.40 | SEK 357.50 +83.9% | 11.3% | SEK 400.00 | SEK 291.00 | n/a | 4 |
| Nov ’23 | SEK 162.20 | SEK 366.60 +126.0% | 11.1% | SEK 403.00 | SEK 291.00 | n/a | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.